Results 1 to 10 of about 12,752 (178)

Benznidazole [PDF]

open access: yesActa Crystallographica Section E, 2008
The conformation of the title compound [systematic name: N-benzyl-2-(2-nitroimidazol-1-yl)acetamide], C12H12N4O3, can be described in terms of the relative orientation of three planar fragments, the imidazol group (A), benzyl group (B), and the ...
Bruno Dacunha-Marinho   +4 more
doaj   +4 more sources

Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA). [PDF]

open access: yesPLoS Neglected Tropical Diseases
IntroductionThe currently recommended 8-week daily benznidazole regimen for Chagas disease is poorly tolerated. While shorter benznidazole monotherapy and combination regimens have been explored, the pharmacokinetic/pharmacodynamic (PK/PD) relationship ...
Frauke Assmus   +9 more
doaj   +2 more sources

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras [PDF]

open access: yesMemorias do Instituto Oswaldo Cruz, 2009
Between 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras ...
Josep M Escribà   +9 more
doaj   +4 more sources

Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. [PDF]

open access: yesPLoS Neglected Tropical Diseases
Anti-trypanosomal therapy is generally recommended for individuals under age 50 with the indeterminate form of Chagas disease to prevent disease progression. However, benznidazole and nifurtimox are associated with adverse drug reactions.
Katherine Reifler   +13 more
doaj   +2 more sources

Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease. [PDF]

open access: yesPLoS Neglected Tropical Diseases
BackgroundThere is an urgent need for improved treatments for Chagas disease, a neglected tropical infection caused by the protozoan parasite Trypanosoma cruzi.
Frauke Assmus   +12 more
doaj   +2 more sources

Clinical Progression of Cardiac Chronic Trypanosoma cruzi Infection in a Long-Term Prospective Cohort from Rural Colombia [PDF]

open access: yesPathogens
Chronic Trypanosoma cruzi infection remains a major cause of preventable cardiomyopathy in Latin America, yet prospective data from endemic rural populations after the interruption of domestic transmission are limited.
Mario J. Olivera   +3 more
doaj   +2 more sources

Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole

open access: yesMicrobiology Spectrum, 2022
Dermatitis is the most common adverse event during treatment with benznidazole in chronic Chagas disease and is probably mediated by T cells. A set of molecules representative of the different type IV hypersensitivity reactions was evaluated in the ...
Melisa D. Castro Eiro   +17 more
doaj   +1 more source

Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2018
BACKGROUND:Drugs currently used for the treatment of Chagas' disease, nifurtimox and benznidazole, have a limited effectiveness and toxic side effects.
Vanesa Puente   +4 more
doaj   +1 more source

Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model

open access: yesPharmaceuticals, 2023
Chagas disease (ChD), caused by Trypanosoma cruzi, is the most serious parasitosis in the western hemisphere. Benznidazole and nifurtimox, the only two trypanocidal drugs, are expensive, difficult to obtain, and have severe side effects. Nitazoxanide has
Minerva Arce-Fonseca   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy